CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

For years, CRISPR Therapeutics (NASDAQ: CRSP) has been the type of stock investors might call a home run swing. The company develops medicines using gene-editing technologies to treat or cure serious conditions and diseases that traditional pharmaceutical drugs cannot.The stock has generated good returns over time, but it's been a very bumpy ride at times. Today, CRISPR Therapeutics' stock trades at a fraction of its former price. However, Wall Street analysts see opportunity. On CNN Business, 58% of Wall Street analysts have rated CRISPR Therapeutics as a buy, with price targets signaling as much as 437% upside.Here's a look at why analysts might be bullish.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool